CANF Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

4.175

Open

4.150

VWAP

4.06

Vol

61.74K

Mkt Cap

5.50M

Low

3.940

Amount

250.34K

EV/EBITDA(TTM)

--

Total Shares

1.31M

EV

2.50M

EV/OCF(TTM)

--

P/S(TTM)

3.59

Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

Show More

Events Timeline

(ET)

2026-03-04

07:10:00

Can-Fite BioPharma Announces Phase IIa Results for Namodenoson

2026-02-17 (ET)

2026-02-17

07:20:00

Can-Fite BioPharma Publishes Study on Namodenoson

2026-02-09 (ET)

2026-02-09

07:20:00

Can-Fite Receives Canadian Patent Approval for Weight Loss Therapy

2026-02-05 (ET)

2026-02-05

07:20:00

Can-Fite BioPharma Patient Successfully Undergoes Liver Transplant

2026-01-20 (ET)

2026-01-20

07:10:00

Can-Fite BioPharma Completes Patient Enrollment in Pancreatic Cancer Trial

2025-12-26 (ET)

2025-12-26

07:10:00

Can-Fite BioPharma Secures Patent in Brazil for Sexual Dysfunction Treatment

2025-12-23 (ET)

2025-12-23

16:50:00

Can-Fite BioPharma Approves 1-for-3,000 Reverse Split

2025-12-16 (ET)

2025-12-16

09:30:00

Can-Fite BioPharma Updates on Clinical Development and Financial Status

News

NASDAQ.COM

03-04NASDAQ.COM

Can-Fite BioPharma's Drug Trial Achieves Success

Benzinga

Can-Fite BioPharma's Drug Trial Success Boosts Shares

Newsfilter

03-04Newsfilter

Can-Fite BioPharma Completes Financing Agreement

Benzinga

U.S. Stocks Rise in Morning Trading, Dow Jones Up Over 100 Points

stocktwits

03-04stocktwits

Can-Fite BioPharma Shares Surge 40% on Positive Trial Results

Yahoo Finance

2025-12-27Yahoo Finance

UiPath to Join S&P Midcap 400 Index Effective January 2, 2026

Valuation Metrics

The current forward P/E ratio for Can Fite Biopharma Ltd (CANF.A) is -0.83, compared to its 5-year average forward P/E of -0.63. For a more detailed relative valuation and DCF analysis to assess Can Fite Biopharma Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-0.63

Current PE

-0.83

Overvalued PE

4.41

Undervalued PE

-5.68

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.15

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.67

Undervalued EV/EBITDA

-0.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

24.05

Current PS

243.93

Overvalued PS

68.10

Undervalued PS

-20.01

Financials

AI Analysis

Annual

Quarterly

Whales Holding CANF

Trading Trends

People Also Watch

Frequently Asked Questions

What is Can Fite Biopharma Ltd (CANF) stock price today?

The current price of CANF is 4.05 USD — it has decreased -3.57

What is Can Fite Biopharma Ltd (CANF)'s business?

Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

What is the price predicton of CANF Stock?

Wall Street analysts forecast CANF stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CANF is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Can Fite Biopharma Ltd (CANF)'s revenue for the last quarter?

Can Fite Biopharma Ltd revenue for the last quarter amounts to 155.00K USD, decreased -21.32

What is Can Fite Biopharma Ltd (CANF)'s earnings per share (EPS) for the last quarter?

Can Fite Biopharma Ltd. EPS for the last quarter amounts to -3.33 USD, decreased -70.00

How many employees does Can Fite Biopharma Ltd (CANF). have?

Can Fite Biopharma Ltd (CANF) has 5 emplpoyees as of March 11 2026.

What is Can Fite Biopharma Ltd (CANF) market cap?

Today CANF has the market capitalization of 5.50M USD.